PATENT CLAIM ANALYSIS

Application Number: 16206694
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["424", "450000"]

Abstract:
Novel encapsulated umirolimus and umirolimus polymer conjugate formulations having enhanced permeability and retention at tumor sites. Also provided are methods for treating cancer by administering the umirolimus formulations.

Claim (Index 1):
A pharmaceutical formulation comprising umirolimus encapsulated in a liposome, and a pharmaceutically acceptable excipient, carrier, or diluent, wherein the liposome has a particle size of 10-200 nm and includes a polyethylene glycol (PEG) conjugated phospholipid (PEGylated phospholipid) and a phosphatidylcholine (PC), the umirolimus is present at a molar ratio of 0.1-10% based on the amount of the PEGylated phospholipid and the PC, and the PEG has a length of 10-3000 monomeric units.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 98.0
- Lexical Diversity: 1.2
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14093876', '14765620', '13916129', '12761588', '12731781']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7031656524959654
- 35 USC 102 Novelty (BERT): 0.508772322352252
- Combined Prediction Score: 0.6837263194815941
- Mean Citation Score: 219.67006
- Max Citation Score: 284.49216
- Similarity Product: 208.17303772865296

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test